Guillain-Barré syndrome (GBS), a rare neurological disorder identified as a potential safety concern with vaccination for respiratory syncytial virus (RSV) in older adults, is seen at a "more common than expected" rate, according to a recent report from Centers for Disease Control and Prevention.
While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."
